FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody, which specifically binds to PCSK9. A pharmaceutical composition containing the specified antibody; a nucleic acid molecule encoding the specified antibody; a vector and a host cell containing the specified nucleic acid molecule; an immunoconjugate containing the specified antibody are also disclosed. The application of the specified antibody in production of a drug for the treatment of dyslipidemia or a drug for facilitating cellular capture of low-density lipoproteins (LDL) is disclosed.
EFFECT: invention has the capability of effective treatment of diseases related to PCSK9.
15 cl, 14 dwg, 3 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| IL-5 BINDING MOLECULE, METHOD OF ITS PREPARATION AND ITS USE | 2021 |
|
RU2811518C1 |
| GIPR ANTIBODY AND ITS GLP-1 FUNCTION PROTEIN AS WELL AS PHARMACEUTICAL COMPOSITION BASED ON IT AND ITS USE | 2019 |
|
RU2800370C2 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| CANINIZED ANTI-HUMAN CTLA-4 ANTIBODIES | 2020 |
|
RU2822460C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
